Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icovamenib in Type 2 Diabetes Not Achieving Glycemic Targets on GLP-1 Therapy
NCT07502508Phase 2Recruiting
- Sponsor
- Biomea Fusion
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icovamenib in type 2 diabetes mellitus (T2DM), sponsored by Biomea Fusion. Started Apr 2026; status: recruiting.
02
Drugs
icovamenib
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07502508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502508.